Compare Sanofi SA (SNY) vs Spotify Technology (SPOT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Spotify Technology — how do they compare? Sanofi SA trades at $40.04 (market cap $95.18B), while Spotify Technology trades at $528.93 (market cap $108.22B). The key difference: Sanofi SA and Spotify Technology are close in size by market cap, and Sanofi SA pays a 6.01% dividend while Spotify Technology pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sanofi SA for 94 Days and Spotify Technology for 111 Days on average.
| SNY | SPOT | |
|---|---|---|
Market Cap | $95.18B | $108.22B |
Volume | 2,995,646 | 1,655,796 |
Sector | Health | Media |
52-Week High | $52.34 | $692.04 |
52-Week Low | $39.51 | $412.75 |
Typical Hold Time | 94 Days | 111 Days |
Enterprise Value | $114.48B | $98.23B |
Dividend Yield | 6.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $40.17, down slightly by 0.07%. The technical outlook is bearish, with price near key support at $40. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21, and revenue for 2025 reached $46.72B. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, signaling growth potential beyond its blockbuster drug Dupixent.
The stock presents a mixed outlook. Positive factors include consistent earnings beats, a high gross margin of 72.77%, and strategic partnerships. However, a bearish technical signal, a projected net income decline to $4.0B in 2026, and a high proportion of analyst hold ratings (51.86%) suggest caution. Key risks involve execution of new drug pipelines and future patent expirations.
Spotify (SPOT) trades at $524.71, up 2.3% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamental improvement with revenue growing from $11.7B in 2022 to $17.2B in 2025, while achieving profitability with net income of $2.2B. Recent earnings show mixed results with Q2 2026 missing expectations, but analyst sentiment remains positive with 62% buy ratings and a $606.50 consensus price target.
The outlook remains favorable with continued revenue growth and margin expansion driving upside potential. Key risks include competitive pressures in streaming and market volatility. With strong institutional support and improving cash flow trends, SPOT presents a growth opportunity despite recent technical overbought conditions near resistance levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Spotify Technology
Spotify Technology S.A. provides music streaming services. The Company offers commercial-free music and ad-supported services to subscribers. Spotify Technology serves clients worldwide.
Read more on SPOT →
